Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.
Cai MC, Cheng S, Wang X, Hu JD, Song YP, Huang YH, Yan ZX, Jiang YJ, Fang XS, Zheng XY, Dong LH, Ji MM, Wang L, Xu PP, Zhao WL. Cai MC, et al. Genome Med. 2020 Apr 30;12(1):41. doi: 10.1186/s13073-020-00739-0. Genome Med. 2020. PMID: 32349779 Free PMC article. Clinical Trial.
The genetic landscape of histologically transformed marginal zone lymphomas.
Li A, Yi H, Deng S, Ruan M, Xu P, Huo Y, Lu H, Shen X, Ouyang B, Cai M, Xu H, Wang Z, Zhang L, Zhu L, Peng Q, Gu Y, Xie J, Wang Y, Dong L, Liu Z, Wang C. Li A, et al. Cancer. 2024 Apr 15;130(8):1246-1256. doi: 10.1002/cncr.35072. Epub 2023 Nov 8. Cancer. 2024. PMID: 37941429
Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial.
Cai MC, Cheng S, Jing HM, Liu Y, Cui GH, Niu T, Shen JZ, Huang L, Wang X, Huang YH, Wang L, Xu PP, Zhao WL. Cai MC, et al. Lancet Reg Health West Pac. 2024 Jul 29;50:101160. doi: 10.1016/j.lanwpc.2024.101160. eCollection 2024 Sep. Lancet Reg Health West Pac. 2024. PMID: 39175480 Free PMC article.
YY1 downregulation underlies therapeutic response to molecular targeted agents.
Zhou S, Zang J, Cai MC, Ye K, Liu J, Ma P, Wu J, Dai C, Lu H, Zhang Q, Jiang J, Chu T, Shen Y, Tan L, Zhuang G, Zhao X, Wang L, Zhuang Y, Fu Y. Zhou S, et al. Among authors: cai mc. Cell Death Dis. 2024 Nov 27;15(11):862. doi: 10.1038/s41419-024-07239-8. Cell Death Dis. 2024. PMID: 39604408 Free PMC article.
Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer.
Zang J, Shahatiaili A, Cai MC, Jin D, Shen P, Qian L, Zhang L, Zhang T, Wu Y, Yang F, Wu Z, Hou Y, Bai Y, Xia J, Cheng L, Zhang R, Zhuang G, Chen H. Zang J, et al. Among authors: cai mc. Clin Cancer Res. 2024 Nov 1;30(21):4920-4931. doi: 10.1158/1078-0432.CCR-24-1277. Clin Cancer Res. 2024. PMID: 39226396
Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer.
Shen P, Ye K, Xiang H, Zhang Z, He Q, Zhang X, Cai MC, Chen J, Sun Y, Lin L, Qi C, Zhang M, Cheung LWT, Shi T, Yin X, Li Y, Di W, Zang R, Tan L, Zhuang G. Shen P, et al. Among authors: cai mc. Sci Adv. 2023 Nov 24;9(47):eadj0123. doi: 10.1126/sciadv.adj0123. Epub 2023 Nov 22. Sci Adv. 2023. PMID: 37992178 Free PMC article.
67 results